AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01087411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo oil capsules
Description: This group will receive capsules containing rape seed oil. Participants will be instructed to lead their life in the same manner as before the intervention but eat three capsules each morning and evening.
Study NCT04116684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Withings Digital Blood Pressure Monitor
Description: This is a home digital blood pressure monitor that can transmit recordings via a user's smartphone.
Study NCT03425630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Argicolina
Description: 8 weeks
Study NCT03425630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normolip
Description: 8 weeks
Study NCT03425630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normolip
Description: 8 weeks
Study NCT03020108 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: 2 cc blood samples will be drawn from antecubital vein
Study NCT04145596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSK3486
Description: HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
Study NCT01862354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverse abdominal plan block
Description: Transverse abdominal plan block was performed after induction of anaesthesia and before surgery. 3 mg/kg of Ropivacaine 5mg/ml (maximum 200 mg) plus 150 microg of Clonidine were injected at the good place. The was realised with the aid of ultrasound
Study NCT01862354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous wound infusion
Description: In this group, a multihole catheter was surgically inserted vertically before skin closure. The catheter was primed with Ropivacaine 2 mg/ml 10 ml plus clonidine 150 microg before the end of anaesthesia. Continuous wound infusion was started at a rate of 10 ml per hour of Ropivacaine 2 mg/ml during the first 9 hours after the surgery.
Study NCT02891603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib Dose and Schedule: 200 mg twice a day (BID) orally from day 0 until day +100. PAC will be tapered to 50% of the total dose at day +70, then 25% of total dose at day +84, then stop at day +100 (+/- 7 days).
Study NCT02028637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TLRs
Description: Recently it has involved the role of TLR (toll-like receptors) in the pathogenesis of asthma.The possible role that TLRs play in the asthma and its recognition as a new endotype asthma, could open new therapeutic expectations.
Study NCT02476383 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal manipulative therapy
Description: refer to arm descriptions
Study NCT01406262 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Albiglutide
Description: once weekly subcutaneous injection
Study NCT01406262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: oral tablet
Study NCT02175043 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: atrial electrogram and liner ablation
Description: 1. The group of positive control is the operation to add in CFAE to conventional liner ablation in persistent atrial fibrillation patients~2. The group of negative is the operation to only doing conventional liner ablation with persistent atrial fibrillation
Study NCT02175043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: atrial electrogram and liner ablation
Description: 1. The group of positive control is the operation to add in CFAE to conventional liner ablation in persistent atrial fibrillation patients~2. The group of negative is the operation to only doing conventional liner ablation with persistent atrial fibrillation
Study NCT03484585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib (BAY1163877)
Description: Single dose, intake orally, 200 mg
Study NCT00199108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depocyt
Study NCT00199108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT04461236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Supplement
Description: Supplement provided in capsules. Half the capsules to be taken with lunch and the other half with dinner. All supplements are commercially available.
Study NCT02891603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus (SIR) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of SIR taper. SIR levels will be monitored according to program standard operating procedures. Dose modifications of SIR for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.
Study NCT04461236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03382080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dream School Program
Description: The Dream School program is a whole school program, involving staff and students, with the aim of creating learning environments where students are confident and experience a sense of belonging, and where mental health is promoted.
Study NCT03382080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health Support Team
Description: MHST is also a whole school project but aimed at specific students at risk of dropping out. It is a systematisation of the student services through~1. Co-location of services and staff working in services~2. One open door to increase accessibility to the services and staff for students~3. Focus on the transition from lower to upper secondary school~4. Close follow-up of students at risk to ensure tailored help to each student~5. Early intervention and follow up when students starts being absent from school This work demands cross- and multidisciplinary collaborations within the MHST, between MHST and school leadership, and between lower and upper secondary schools.
Study NCT02497092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Technique of injection
Study NCT02891603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus (TAC) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of TAC taper. TAC levels will be monitored according to program standard operating procedures. Dose modifications of TAC for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.
Study NCT01781429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVD-523
Description: Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
Study NCT03533140 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DUCEST Neurostimulator V Group A
Description: The DUCEST Neurostimulator V needle-electrodes are applied post-operatively to stimulate the R.auricularis of the vagus nerve located at the Fossa triangularis. Connecting the needle-electrode cables to the Neurostimulator V activates the device. (The stimulation intensity can be adjusted from 0,05mA to 1,2mA, default value is 0,4mA). The starting stimulation intensity will be adjusted to 1mA and takes place at 1Hz continuously for 40 minutes, followed by a 20 minute break. The built-in 3V battery lasts for approx. 14 days. After 7 days the electrodes are replaced and applied to the other ear of the patient. A plaster with a plastic mounting clip is attached on the shoulder of the patient. The Neurostimulator is connected to the mounting clip. After 14 days or at hospital discharge of the patient, the device is unmounted and the needle-electrodes are removed.
Study NCT03533140 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DUCEST Neurostimulator V Group B
Description: The DUCEST Neurostimulator V needle-electrodes are applied post-operatively at the Fossa triangularis. Connecting the needle-electrode cables to the Neurostimulator V activates only the signal lamp but not the device.
Study NCT03614169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of a HIS-pacing lead
Description: This intervention is attempted first
Study NCT02891603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogenic hematopoietic cell transplant (alloHCT)
Description: Patients will undergo allogenic hematopoietic cell transplant (alloHCT) as a part of their standard of care treatment.
Study NCT03614169 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of a LV-pacing lead
Description: This intervention is attempted first
Study NCT01591226 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: gelatine capsule 6mg/kg bodyweight 60min prior test
Study NCT01591226 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Citrate
Description: 0.5g/kg bodyweight diluted in 7dl water ingested 120-90min prior test
Study NCT01591226 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test
Study NCT01591226 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test
Study NCT01591226 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride
Description: sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
Study NCT02545062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MoCa test
Description: The MoCa test is actually used for the screening of Mild Cognitive Impairment . It is a one page 30 points test that can be done in 10 minutes in a routine annual visit to the Diabetes Clinic. The MoCa assesses several cognitive domains, and it is available in hebrew language.
Study NCT01591226 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
Study NCT03086317 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Catheter-Directed Thrombolysis
Description: Catheter-directed thrombolysis requires placement of a multi-sidehole infusion catheter within the pulmonary arterial thrombus burden, under angiographic guidance. Thrombolytic medications are slowly infused through the catheter, which is left in place for the duration of the treatment. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
Study NCT03086317 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-Accelerated Thrombolysis
Description: USAT is a modification of standard catheter-directed thrombolysis utilizing a proprietary system of local high frequency, low-power ultrasound to dissociate the fibrin matrix of the thrombus, allowing deeper penetration of lytic medication. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
Study NCT02808312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablet(s) administered orally in a fed state on Day 1
Study NCT04949906 — intervention group
Intervention type: DRUG
Intervention: Raise serum brain granules
Description: Should Yangseronao granules be used in patients undergoing intravenous thrombolysis for the diagnosis of acute ischemic stroke
Study NCT02444754 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Obtain medical data
Study NCT02444754 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete demographics questionnaires
Study NCT02444754 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study NCT03038620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
Study NCT04949906 — intervention group
Intervention type: DRUG
Intervention: No nourishing serum brain granules are used
Description: No nourishing serum brain granules are used
Study NCT03038620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
Study NCT03808571 — intervention group
Intervention type: OTHER
Intervention: cord blood specimen during the delivery
Description: The cord blood will be taken during the delivery of baby.
Study NCT03035630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10mg/kg IV over 60 minutes on D1 and D15 of every 28 day cycle
Study NCT03035630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 50 mg once daily from D1 to D14 of every 21 day cycle
Study NCT04136171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplontersen
Description: Eplontersen by subcutaneous injection
Study NCT04136171 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eplontersen-matching placebo by subcutaneous injection
Study NCT00049543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given PO
Study NCT00049543 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT00049543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00049543 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02296125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 80 mg/40 mg + placebo
Description: The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT02296125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Erlotinib 150/100mg
Description: The initial dose of Placebo Erlotinib 150 mg once daily can be reduced to Placebo 100 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT02296125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Gefitinib 250 mg
Description: The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT02296125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib 150/100 mg
Description: The initial dose of Erlotinib 150mg once daily can be reduced to 10 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291).
Study NCT02296125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib 250 mg
Description: The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291).
Study NCT02296125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo AZD9291 80 mg/ 40 mg
Description: The initial dose of Placebo AZD9291 80 mg once daily can be reduced to Placebo AZD9291 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT01923922 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: CT Perfusion
Description: The CT perfusion scan will be performed on a multi-detector CT scanner at the time of routine preoperative neuronavigation imaging. A non-contrast CT head scan will be acquired to localize the tumour. Four 5 mm thick slices will be selected at the level of the tumour. Multiple images will be acquired at each levels starting 5 sec after the injection of 50 cc of non-ionic iodinated contrast media at a rate of 4 cc/sec. The acquisition parameters will be 80 kVp and 100 mA. The images will be acquired every second for a total of 110 sec. The post- processing will be performed and parameters will be calculated using regions of interest in the areas of tumour showing the highest perfusion values. Another region of interest will be placed in the contralateral normal looking white matter.
Study NCT01481610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumiracoxib
Description: Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day), for a period no longer than 10 days, but no shorter than 7 days.
Study NCT01481610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
Study NCT02106832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (BAYQ3939) dry powder for inhalation
Description: Ciprofloxacin dry powder for inhalation (DPI) 32.5 mg inhaled twice daily in cycles of 28 days on-treatment and 28 days off-treatment.
Study NCT02106832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (BAYQ3939) dry powder for inhalation
Description: Ciprofloxacin DPI 32.5 mg inhaled twice daily in cycles of 14 days on-treatment and 14 days off-treatment.
Study NCT02106832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo inhaled twice daily intermittently for 28 days on / 28 days off
Study NCT02106832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo inhaled twice daily intermittently for 14 days on / 14 days off
Study NCT01907893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Collaborative Care Plus Treatment as Usual
Study NCT01490268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil, Hydromorphone
Description: Intraoperatively: Target controlled infusion with 0.4 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
Study NCT01490268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil, Hydromorphone
Description: Intraoperatively: Target controlled infusion with 0.8 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
Study NCT02935218 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parenting Skills for Mothers with BPD
Description: The cognitive-behavioral Group Training for mothers with BPD consists of 12 weekly sessions promoting parenting skills including primary needs of children, stress and stress management, dealing with conflicts, mindfulness, emotion regulation, routine and flexibility, the role of the body in parenting, basic assumptions about parenting, and self-care.
Study NCT02362685 — intervention group
Intervention type: DEVICE
Intervention: functional test
Description: subjects perform a metabolic exercise testing
Study NCT03564171 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: stress counseling, exercise, nutritional counseling, smoking cessation counseling
Study NCT02362685 — intervention group
Intervention type: GENETIC
Intervention: matching genotype with phenotype
Study NCT02856581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Given PO